Navigation Links
BioMed Realty Trust Declares Third Quarter 2008 Common Stock and Preferred Stock Dividends
Date:9/15/2008

/p>

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 based on current expectations, forecasts and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially. These risks and uncertainties include, without limitation: general risks affecting the real estate industry (including, without limitation, the inability to enter into or renew leases, dependence on tenants' financial condition, and competition from other developers, owners and operators of real estate); adverse economic or real estate developments in the life science industry or the company's target markets; risks associated with the availability and terms of financing and the use of debt to fund acquisitions and developments; failure to manage effectively the company's growth and expansion into new markets, or to complete or integrate acquisitions and developments successfully; risks and uncertainties affecting property development and construction; risks associated with downturns in the national and local economies, increases in interest rates, and volatility in the securities markets; potential liability for uninsured losses and environmental contamination; risks associated with the company's potential failure to qualify as a REIT under the Internal Revenue Code of 1986, as amended, and possible adverse changes in tax and environmental laws; and risks associated with the company's dependence on key personnel whose continued service is not guaranteed. For a further list and description of such risks and uncertainties, see the reports filed by the company with the Securities and Exchange Commission, including the company's most recent annual report on Form 10-K and quarterly reports on Form 10-Q. The company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.


'/>"/>
SOURCE BioMed Realty Trust, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Johnson & Johnson Honors 2008 Recipients of The Dr. Paul Janssen Award for Biomedical Research
2. Plexus Systems, Inc. to Exhibit at BIOMEDevice Medical Technology Conference
3. Sinobiomed Retains CB Capital Partners as Financial Advisor to Maximize Shareholder Value
4. Regenesis Biomedical Announces Additions to Board of Directors
5. ArunA Biomedical Announces Exclusive Worldwide Technology Licensing Agreement to Commercialize Human Embryonic Stem Cell Derived Mesenchymal Cells
6. Vista Partners Updates Coverage on Inovio Biomedical Corporation (Amex: INO); $3.57 Price Target
7. ArunA Biomedical Names William T. Sharp President and Chief Executive Officer
8. Roche and Response Biomedical Corporation Aim to Reduce Vein-to-Brain Time with New Point-of-Care Cardiac Tests
9. Frontage Laboratories Completes Acquisition of Advanced Biomedical Research, Inc. (ABR)
10. Medicare Exemplary Provider Accreditation Awarded to Regenesis Biomedical
11. HIPAA Privacy Rule Impedes Biomedical Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... February 27, 2015 The fully ... (Nexera UC) can sequentially analyze up to 48 ... with high-sensitivity detection of targets by mass spectrometry. ... to fulfill the measurement requirements of a wide ... products, drug delivery and search for disease biomarkers, ...
(Date:2/27/2015)... , Feb. 27, 2015  Pfenex Inc. (NYSE MKT: ... of biosimilar therapeutics, today announced that it will be ... Marquis on March 2 nd at 3pm PST. Patrick ... a panel discussing the current state of the biosimilar ... . For more information on CALBIO ...
(Date:2/27/2015)... Francisco, CA (PRWEB) February 27, 2015 ... joining forces on February 28 with patients and health ... raise awareness for Rare Disease Day®. Rare Disease ... diseases and calling attention to the special challenges faced ... around them. , “Cytokinetics is proud to stand alongside ...
(Date:2/27/2015)... Feb. 27, 2015   PureTech , a science ... commercializing disruptive products and technologies in the healthcare sector, ... former CEO and Member of the Board of Directors ... "It,s has been a pleasure to know Chris ... we will be working together more closely now," said ...
Breaking Biology Technology:Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 2Shimadzu Corporation Launches Nexera UC - The World’s Foremost Unified Chromatography System 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 2Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 3Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 4Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 5Cytokinetics Joins Global Movement to Raise Awareness for Rare Diseases 6Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 2Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 3Christopher Viehbacher, former CEO of Sanofi, Joins PureTech's Board of Directors 4
... Therapeutics Inc. (TSX:,LOR, AMEX: LRP) ("Lorus" or ... research and development of pharmaceutical products and,technologies ... progress made in,the Virulizin(R) development program, including ... Virulizin(R) mode of action and the issuance ...
... Alexza,Pharmaceuticals, Inc. (Nasdaq: ALXA ) announced ... Vice President, Global Supply Chain and,Sustainment Engineering. He ... of Alexza,s global supply chain strategy to,support the ... lead program, AZ-004 (Staccato(R) loxapine) is in,Phase 3 ...
... ... Advisory Board --, SAN DIEGO, July 9 ... has received regulatory approval to,begin a Phase 2a proof-of-concept clinical trial ... arthritis, is a,painful and debilitating disease caused by abnormally elevated levels ...
Cached Biology Technology:Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 2Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 3Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 4Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 5Lorus Therapeutics Provides an Update on Progress in Virulizin(R) Development Program 6Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering 2Christopher Kurtz Joins Alexza Pharmaceuticals as Vice President, Global Supply Chain and Sustainment Engineering 3Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout 2Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout 3Ardea Biosciences' Advances RDEA806 Into Phase 2a Proof-of-Concept Study for Gout 4
(Date:2/5/2015)... Jan. 27, 2015   Marvin Test ... deployed, innovative test solutions for military, aerospace, ... of its TS-323 GENASYS Test Platform ... (LMSSC). GENASYS is a high-performance PXI-based system ... applications that require performance functional testing. GENASYS ...
(Date:2/5/2015)... , Jan. 30, 2015  It is gratifying ... power and potential for genomic science as a means ... disease prevention and treatment.  I was honored to participate ... government-funded precision medicine program. Since the ... science of genomics—from the first sequenced genome of a ...
(Date:1/22/2015)... - Today, FindBiometrics, the leading source of biometrics industry news, interviews ... design. "When we launched FindBiometrics 12 years ago ... , founder and CEO of FindBiometrics. "Now it,s maturing very ... key players on a very broad scale.  We are known ...
Breaking Biology News(10 mins):Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 2Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 3Marvin Test Solutions' GENASYS Platform Advances Mission-Critical Aerospace Production Test 4J. Craig Venter, Ph.D., Co-Founder and CEO, Human Longevity, Inc. (HLI) Participates in White House Precision Medicine Event 2Identity Industry Leading Publication Debuts New Look As Biometrics Hit Mainstream 2
... potential for an outbreak of the phenomenon commonly called ... spring and summer, according to researchers with the Woods ... (NCSU). This advisory is based in part ... Alexandrium fundyense the algae notorious ...
... international team of researchers from China and the United ... Early Cretaceous rocks in the southern part of the ... Jiayuguan, Gansu Province, China. Two of their discoveries represent ... in technical publications published on-line in the Proceedings ...
... in French . Scientists at the ... Japan along with researchers from McGill University and other ... are controlled in mammals. Three years of intensive research by ... publication of several milestone scientific papers in Nature Genetics ...
Cached Biology News:Researchers report 'moderately large' potential for red tide outbreak in Gulf of Maine region 2Researchers report 'moderately large' potential for red tide outbreak in Gulf of Maine region 3Researchers report 'moderately large' potential for red tide outbreak in Gulf of Maine region 4Field Museum paleontologist leads study on two new dinosaurs from China 2Field Museum paleontologist leads study on two new dinosaurs from China 3Field Museum paleontologist leads study on two new dinosaurs from China 4Major international study challenges notions of how genes are controlled in mammals 2
... early protein. Can detect ... exhibiting an intranuclear inclusion staining ... 6-24 hours. These antibodies ... staining. No other nuclear ...
MAb to Vasopressin Preservative: NaN3...
Mouse monoclonal [0.N.509] to PCTAIRE2 ( Abpromise for all tested applications). entrezGeneID: 5128 SwissProtID: Q00537...
MMP-2 / MMP-9 Inhibitor IV is a potent, selective, slow binding and mechanism based inhibitor of human gelatinases. • Molecular weight: 306.4 • Molecular Formula: C(15)H(14)O(3)S(2). &bul...
Biology Products: